Inter occasion variability in individual optimal design

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 42, Issue 6, 2015, Pages 735-750

  Kristoffersson, Anders N ^a   Friberg, Lena E ^a   Nyberg, Joakim ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bayesian; Fisher information; Inter occasion variability (IOV); Maximum a posteriori (MAP); Optimal design (OD); Pharmacometrics; Shrinkage

Indexed keywords

COLISTIMETHATE; COLISTIN; ANTIINFECTIVE AGENT; COLISTINMETHANESULFONIC ACID; PRODRUG;

ANALYTICAL ERROR; ARTICLE; DRUG CLEARANCE; INTER OCCASION VARIABILITY; MAXIMUM A POSTERIORI; MAXIMUM PLASMA CONCENTRATION; NONLINEAR SYSTEM; PREDICTION; PRIORITY JOURNAL; SIMULATION; STATISTICAL MODEL; STATISTICAL PARAMETERS; VARIANCE; ANALOGS AND DERIVATIVES; ANIMAL; BAYES THEOREM; BIOLOGICAL MODEL; BIOTRANSFORMATION; COMPARATIVE STUDY; DRUG ADMINISTRATION; HUMAN; METHODOLOGY; REPRODUCIBILITY; STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA; TISSUE DISTRIBUTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BAYES THEOREM; BIOTRANSFORMATION; COLISTIN; DATA INTERPRETATION, STATISTICAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PRODRUGS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TISSUE DISTRIBUTION;

EID: 84945490276     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-015-9449-6     Document Type: Article

References (24)

1. Karlsson MO, Sheiner LB (1993) The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21(6):735–750. doi:10.1007/bf01113502
2. Savic R, Karlsson M (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558–569. doi:10.1208/s12248-009-9133-0
3. Mandema J, Verotta D, Sheiner L (1992) Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20(5):511–528. doi:10.1007/bf01061469
4. Maitre PO, Bührer M, Thomson D, Stanski DR (1991) A three-step approach combining bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm 19(4):377–384. doi:10.1007/bf01061662
5. Rousseau A, Marquet P (2002) Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 16(4):253–262. doi:10.1046/j.1472-8206.2002.00086.x
6. Lacroix BD, Friberg LE, Karlsson MO (2012) Evaluation of IPPSE, an alternative method for sequential population PKPD analysis. J Pharmacokinet Pharmacodyn 39(2):177–193. doi:10.1007/s10928-012-9240-x
7. Atkinson A, Donev A (1992) Optimum experimental designs. Oxford statistical science series, vol 8. Clarendon Press, Oxford
8. Merlé Y, Mentré F (1995) Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model. J Pharmacokinet Pharmacodyn 23(1):101–125. doi:10.1007/bf02353788
9. Panetta J, Wilkinson M, Pui C-H, Relling M (2002) Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. J Pharmacokinet Pharmacodyn 29(2):171–188. doi:10.1023/a:1019755608555
10. Hennig S, Nyberg J, Fanta S, Backman JT, Hoppu K, Hooker AC, Karlsson MO (2012) Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporin. J Clin Pharmacol 52(3):347–360. doi:10.1177/0091270010397731
11. Merlé Y, Mentré F (1999) Optimal sampling times for bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring. J Pharmacokinet Biopharm 27(1):85–101. doi:10.1023/a:1020634813296
12. Yu J, Goos P, Vandebroek M (2012) A comparison of different Bayesian design criteria for setting up stated preference studies. Transp Res Part B 46(7):789–807. doi:10.1016/j.trb.2012.01.007
13. Falagas ME, Kasiakou SK, Saravolatz LD (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40(9):1333–1341. doi:10.1086/429323
14. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, LE Friberg (2012) Application of a loading dose of colistin methanesulphonate (CMS) in critically ill patients: population pharmacokinetics, protein binding and prediction of bacterial kill. Antimicrob Agents Chemother. doi:10.1128/aac.06426-11
15. Combes F, Retout S, Frey N, Mentré F (2013) Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics. Pharm Res. doi:10.1007/s11095-013-1079-3
16. Beal S, Sheiner LB, Boeckmann A, Bauer RJ (1989–2011) NONMEM User’s Guides. Icon Development Solutions, Ellicott City, MD, USA
17. Retout S, Mentré F (2003) Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. J Biopharm Stat 13(2):209–227. doi:10.1081/BIP-120019267
18. Nyberg J, Ueckert S, Strömberg EA, Hennig S, Karlsson MO, Hooker AC (2012) PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool. Comput Methods Programs Biomed 108(2):789–805. doi:10.1016/j.cmpb.2012.05.005
19. Lindbom L, Pihlgren P, Jonsson N (2005) PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79(3):241–257
20. ® VI. Korean J Physiol Pharmacol 16(2):97–106
21. Jonsson EN, Wade J, Karlsson M (1996) Comparison of some practical sampling strategies for population pharmacokinetic studies. J Pharmacokinet Biopharm 24(2):245–263. doi:10.1007/bf02353491
22. Holford NHG (1999) Target concentration intervention: beyond Y2K. Br J Clin Pharmacol 48(1):9–13. doi:10.1046/j.1365-2125.1999.00971.x
23. Nguyen L, Tranchand B, Puozzo C, Variol P (2002) Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 53(5):459–468. doi:10.1046/j.1365-2125.2002.01581.x
24. Nyberg J, Höglund R, Bergstrand M, Karlsson M, Hooker A (2012) Serial correlation in optimal design for nonlinear mixed effects models. J Pharmacokinet Pharmacodyn 39(3):239–249. doi:10.1007/s10928-012-9245-5